{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:03:19Z","timestamp":1717459399400},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T00:00:00Z","timestamp":1412208000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1752-1947-8-325","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T09:04:35Z","timestamp":1412240675000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report"],"prefix":"10.1186","volume":"8","author":[{"given":"Katarzyna","family":"Krawczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Ga\u0142\u0105zka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Grucha\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander B","family":"Skotnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,2]]},"reference":[{"key":"2946_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin\u2019s Lymphoma. Version 1. 2014, 12\/20\/13. 2014, [http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf]"},{"issue":"Suppl 7","key":"2946_CR2","doi-asserted-by":"publisher","first-page":"vii78","DOI":"10.1093\/annonc\/mds273","volume":"23","author":"H Tilly","year":"2012","unstructured":"Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, Andre M, Pfreundschuh M, Dreyling M: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012, 23 (Suppl 7): vii78-vii82.","journal-title":"Ann Oncol"},{"key":"2946_CR3","first-page":"321","volume-title":"2011 Educational Book","author":"C Gisselbrecht","year":"2011","unstructured":"Gisselbrecht C, Mounier N: Novel agents for diffuse large B-cell lymphoma. 2011 Educational Book. 2011, Alexandria, VA: American Society of Clinical Oncology, 321-325."},{"key":"2946_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","volume":"77","author":"L Lu","year":"2009","unstructured":"Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009, 77: 78-86. 10.1016\/j.mvr.2008.08.003.","journal-title":"Microvasc Res"},{"key":"2946_CR5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008, 140: 36-45.","journal-title":"Br J Haematol"},{"key":"2946_CR6","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001, 194: 1861-1874. 10.1084\/jem.194.12.1861.","journal-title":"J Exp Med"},{"key":"2946_CR7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999, 163: 380-386.","journal-title":"J Immunol"},{"key":"2946_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2009","unstructured":"Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009, 58: 1033-1045. 10.1007\/s00262-008-0620-4.","journal-title":"Cancer Immunol Immunother"},{"key":"2946_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","volume":"128","author":"T Hayashi","year":"2005","unstructured":"Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005, 128: 192-203. 10.1111\/j.1365-2141.2004.05286.x.","journal-title":"Br J Haematol"},{"key":"2946_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","volume":"117","author":"AK Hsu","year":"2011","unstructured":"Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS: The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011, 117: 1605-1613. 10.1182\/blood-2010-04-278432.","journal-title":"Blood"},{"key":"2946_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1124\/jpet.102.048496","volume":"305","author":"PH Schafer","year":"2003","unstructured":"Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW, Stirling DI: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003, 305: 1222-1232. 10.1124\/jpet.102.048496.","journal-title":"J Pharmacol Exp Ther"},{"key":"2946_CR12","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","volume":"14","author":"L Wu","year":"2008","unstructured":"Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB: Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008, 14: 4650-4657. 10.1158\/1078-0432.CCR-07-4405.","journal-title":"Clin Cancer Res"},{"key":"2946_CR13","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3324\/haematol.2013.085134","volume":"98","author":"A Chiappella","year":"2013","unstructured":"Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U, Fondazione Italiana Linfomi: Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica. 2013, 98: 1732-1738. 10.3324\/haematol.2013.085134.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"2946_CR14","first-page":"168","volume":"31","author":"G Nowakowski","year":"2013","unstructured":"Nowakowski G, Reeder CB, Foran JM, Porrata LF, Macon WR, Johnston PB, Rivera CE, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE: Combination of lenalidomide with RCHOP (R2CHOP) overcomes negative prognostic impact of non-GCB phenotype in DLBCL\u2014a phase 2 study. Hematol Oncol. 2013, 31 (Suppl 1): 168-abstract 213","journal-title":"Hematol Oncol"},{"key":"2946_CR15","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/leu.2011.165","volume":"25","author":"GS Nowakowski","year":"2011","unstructured":"Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE: Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011, 25: 1877-1881. 10.1038\/leu.2011.165.","journal-title":"Leukemia"},{"key":"2946_CR16","doi-asserted-by":"crossref","first-page":"\u22a0","DOI":"10.1182\/blood.V120.21.689.689","volume":"120","author":"GS Nowakowski","year":"2012","unstructured":"Nowakowski GS, LaPlant BR, Reeder C, Foran JM, Porrata LF, Macon WR, Johnston PB, Rivera CE, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE: Combination of lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-cell lymphomas - a phase II study. Blood. 2012, 120: \u22a0-abstract 689","journal-title":"Blood"},{"key":"2946_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2012.172","volume":"27","author":"H Tilly","year":"2013","unstructured":"Tilly H, Morschhauser F, Salles G, Casasnovas RO, Feugier P, Molina TJ, Jardin F, Terriou L, Haioun C, Coiffier B: Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia. 2013, 27: 252-255. 10.1038\/leu.2012.172.","journal-title":"Leukemia"},{"key":"2946_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","volume":"15","author":"U Vitolo","year":"2014","unstructured":"Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G, Fondazione Italiana Linfomi: Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014, 15: 730-737. 10.1016\/S1470-2045(14)70191-3.","journal-title":"Lancet Oncol"},{"key":"2946_CR19","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008, 26: 4952-4957. 10.1200\/JCO.2007.15.3429.","journal-title":"J Clin Oncol"},{"key":"2946_CR20","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS: An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol. 2011, 22: 1622-1627. 10.1093\/annonc\/mdq626.","journal-title":"Ann Oncol"},{"key":"2946_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","volume":"11","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M: Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011, 11: 462-466. 10.1016\/j.clml.2011.02.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"2946_CR22","first-page":"95","volume":"97","author":"M Wang","year":"2012","unstructured":"Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L: Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. Haematologica. 2012, 97 (Suppl 1): 95-abstract 0237","journal-title":"Haematologica"},{"key":"2946_CR23","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/leu.2013.95","volume":"27","author":"M Wang","year":"2013","unstructured":"Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L: Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013, 27: 1902-1909. 10.1038\/leu.2013.95.","journal-title":"Leukemia"},{"key":"2946_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/hon.2049","volume":"31","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Pellegrini C, Derenzini E, Argnani L, Pileri S: Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed\/refractory diffuse large B-cell lymphoma patients. Hematol Oncol. 2013, 31: 223-224. 10.1002\/hon.2049.","journal-title":"Hematol Oncol"},{"key":"2946_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenberger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000, 403: 503-511. 10.1038\/35000501.","journal-title":"Nature"},{"key":"2946_CR26","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenberger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, L\u00f3pez-Guillermo A: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346: 1937-1947. 10.1056\/NEJMoa012914.","journal-title":"N Engl J Med"},{"key":"2946_CR27","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1002\/cncr.26135","volume":"117","author":"FJ Hernandez-Ilizaliturri","year":"2011","unstructured":"Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS: Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011, 117: 5058-5066. 10.1002\/cncr.26135.","journal-title":"Cancer"},{"key":"2946_CR28","unstructured":"NCT01856192: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma. [http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01856192]"},{"key":"2946_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","volume":"160","author":"LH Zhang","year":"2013","unstructured":"Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R: Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013, 160: 487-502. 10.1111\/bjh.12172.","journal-title":"Br J Haematol"},{"key":"2946_CR30","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events, version 4.0. 2009, [http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html]"},{"key":"2946_CR31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/107327481201900305","volume":"19","author":"JL Cultrera","year":"2012","unstructured":"Cultrera JL, Dalia SM: Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control. 2012, 19: 204-213.","journal-title":"Cancer Control"},{"key":"2946_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346: 235-242. 10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"key":"2946_CR33","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005, 23: 4117-4126. 10.1200\/JCO.2005.09.131.","journal-title":"J Clin Oncol"},{"key":"2946_CR34","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B, German High-Grade Lymphoma Study Group (DSHNHL): Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012, 13: 1250-1259. 10.1016\/S1470-2045(12)70481-3.","journal-title":"Lancet Oncol"},{"key":"2946_CR35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/asheducation.V2012.1.410.3798518","volume":"2012","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C: Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?. Hematology Am Soc Hematol Educ Program. 2012, 2012: 410-416.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2946_CR36","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Bri\u00e8re J, Moskowitz CH, Schmitz N: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010, 28: 4184-4190. 10.1200\/JCO.2010.28.1618.","journal-title":"J Clin Oncol"},{"key":"2946_CR37","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.1998.16.10.3264","volume":"16","author":"C Guglielmi","year":"1998","unstructured":"Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D, Cahn JY, Somers R, Sonneveld P, Gisselbrecht C, Van Der Lelie H, Chauvin F: Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998, 16: 3264-3269.","journal-title":"J Clin Oncol"},{"key":"2946_CR38","doi-asserted-by":"publisher","first-page":"498342","DOI":"10.1155\/2012\/498342","volume":"2012","author":"A Chiappella","year":"2012","unstructured":"Chiappella A, Vitolo U: Lenalidomide in diffuse large B-cell lymphomas. Adv Hematol. 2012, 2012: 498342-","journal-title":"Adv Hematol"},{"key":"2946_CR39","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1200\/JCO.2011.34.7252","volume":"29","author":"JL Rubenstein","year":"2011","unstructured":"Rubenstein JL, Treseler PA, Stewart PJ: Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol. 2011, 29: e595-e597. 10.1200\/JCO.2011.34.7252.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-8-325\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T10:18:22Z","timestamp":1717409902000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-8-325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2946"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-8-325","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,2]]},"assertion":[{"value":"15 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"325"}}